QUALITY ASSURANCE & AUDIT
|
|
- Clarence Houston
- 6 years ago
- Views:
Transcription
1 QUALITY ASSURANCE & AUDIT Birinder Kaur Senior Pharmacist Pharmacy Dept National University Of Malaysia Medical Centre Kuala Lumpur
2 LEARNING OBJECTIVES To define quality assurance and state the importance of implementation in cytotoxic preparation and handling the products. List factors and procedures involved in cytotoxic preparation To ensure that end-product results acceptable quality and the adequacy of staff safety when handling these cytotoxic products To identify relevant references and tools that can be incorporated in your practice
3 Quality Assurance (QA) Refers to a program for the systematic monitoring and evaluation of the various aspects of a service or facility to ensure that standards of quality are being met. Gives CONFIDENCE in a product.
4 Quality Assurance (QA) 2 KEY PRINCIPLES Fit for Purpose The product should be suitable for the intended purpose Right First Time Error-free
5 Why QA is needed? Healthcare Personnel s Perspective Occupational exposure - Dermal contamination - Airborne contamination - Oral contamination Signs and symptoms - Skin rashes - Infertility, miscarriage, birth defects - Leukemia, other cancers
6 What can Affect Quality? Drug Procedures/ Work Processes Audit Personnel Facilities & Equipment
7 Factors Involved Policies & Procedures Facilities & Equipment Aseptic Technique& Product Preparation Personnel education, training & evaluation Storage & Handling within the pharmacy Process validation Expiration dating Labeling Documentation End-product evaluation
8 Policies & Procedures Up to date Available to all involved personnel Should be updated when changes occurs Specific to handling cytotoxic drugs Personnel education & training requirements Preparation technique Process validation Labeling Use & maintenance of facilities & equipment Product acquisition Storage & handling of products & supplies
9 Policies & Procedures Master formula and worksheets Personnel Garb Describe environmental monitoring devices & techniques such as air velocity, temperature & pressure meters Cleaning materials & disinfecting procedures
10 Facilities & Equipment
11 Facilities & Equipment Laminar Airflow/Biohazard Safety Cabinets Laminar Flow Cabinets (LFC)s are not suitable for the preparation of hazardous drugs. Biohazard safety cabinets (BSCs) should be used instead,with a vertical downward airflow exhausting vertically from the cabinet and not towards the operator PIC/S Guide to good practice for preparation of medicinal products in healthcare establishments-april
12 Facilities & Equipment Biological Safety Cabinets (BSC) Re-circulation in BSC of air :0/30/70% Running 24h/day:7 day/week Alarm for insufficient exhaust Alarm for insufficient internal flow External exhaust.pressure BSC Validation 6-12 months - DOP - Leak - Air velocity - Smoke -Temp -Microbiology - Noise - KI disk DOP=dioctyl phtalate KI= potassium iodine ISOPP Safe Handling Standards
13 Facilities & Equipment Pharmaceutical Isolator A containment device which utilises barrier technology to provide an enclosed controlled workspace Positive or negative pressure Running 24h/day:7 day/week Alarm for insufficient exhaust Alarm for insufficient internal flow Double HEPA air filtration (inlet/outlet) Preparation with attached rubber gloves/half suit Validation 6-12 months - DOP -Leak - Air speed - Microbiology PIC/S Guide to good practice for preparation of medicinal products in healthcare establishments-april ISOPP Safe Handling Standard
14 Surface Environmental Sampling Recommendation USP<797>2008 Frequency: - Initially - At least every 6 months If measurable level of Contamination: - Identify cause of contamination - Document - Contain - Retraining - Cleaning (high ph soap & water) - Improving engineering controls Sample localizations: - Working area of BSCs and CACIs - Counter Tops (finished preparation) - Areas adjacent to BSCs/ CACIs (Floor) - Patient administration areas BSC: Biological Safety Cabinets CACI: Compounding Aseptic Containment Isolator Engineering controls improvements Venting BSCs/CACIs 100% to outside Implement CTSD Re-assessing type of BSCs /CACIs CTSD= Close System Transfer Device USP United States Pharmacopeia. Pharmaceutical compounding sterile preparations (general chapter 797) in: second supplement to UPS 31-NF 26: 2008
15 Maintenance of Premise More GMP related but important for the patients safety!! Validation tests for cleanrooms should be performed once a year and pass standards Some parameters: - Grade of room (B or C) and workstation (A) - Air changes/hour: 20 - Pressure difference: Pa Tests included: - Particle Count Test - HEPA Filter Patency Test - Temp Test - Humidity Gradient Test - Lighting Level Test - Sound Test - Bacteriological Test GMP= Good Manufacturing Practice Singapore Guidelines for Safe Handling of Cytotoxic Drugs ISOPP Safe Handling Standards
16 Microbiological Monitoring Premises environmental monitoring cleaning and disinfection People operator broth transfer tests hand cleaning and disinfection
17 Environmental Control and Monitoring Evaluated by measuring the viable particles in the environment Count reported as colony forming unit (cfu) per cubic metre is a measure of microbial contamination Air sampling carried out at least once a month using an air sampler set for sampling 320 litres for 8 minutes Each sampling exercise must be carried out using two types of agar strips/plates: - TSA for total count at 30 35C for 48 hours - Rose Bengal-Agar for yeast and mould 28 30C for 120hours If counts >1cfu per cubic metre no preparations to be done in that cabinet Remedial actions to be carried out and cause of contamination traced Singapore Guidelines for Safe Handling of Cytotoxic Drugs
18 Personnel Education, Training & Evaluation Basic concepts of cytotoxic reconstitution Written and practical training Clinical, Pharmaceutical & Chemical drug properties Facilities, Equipment & supplies Cytotoxic Reconstitution Documentation ASHP Guidelines on Quality Assurance for Pharmacy Prepared Sterile Products ASHP: American Society Of Health-System Pharmacists
19 Personnel Education, Training & Evaluation Proper gowning & gloving technique General conduct in the controlled area Principles of GMP Cleanroom design Aware of safety measures on handling CD GMP: Good Manufacturing Practice ASHP Guidelines on Quality Assurance for Pharmacy Prepared Sterile Products ASHP: American Society Of Health-System Pharmacists
20 Cytotoxic Drug Reconstitution Drug Reconstitution With Needle and Syringe Drug Transfer With Needle and Syringe Chemospike Filter Needles Dispensing Pin Closed System Drug- Transfer Device eg:phaseal, ICU Medical Choice Of Device Dependant on Degree of Safety & Quality of Device ISOPP Safe Handling Standards: Must Be Air Tight & LeakProof
21 Safety Devices/Terminology Closed system drug transfer device (NIOSH) A device that mechanically prohibits the transfer of environmental contaminants into the system and the escape of hazardous drugs or vapor concentrations outside the system US ASHP Guideline QA sterile products Closed system = aseptic transfer of sterile nonpyrogenic finished pharmaceuticals (e.g. from vials or ampoules) obtained from licensed manufacturer into sterile final containers NIOSH= National Institute for Occupational Safety and Health, available at
22 Expiration Dating Should be done on a product by product basis & be based on currently available drug stability information & sterility considerations consider all aspects of sterile product, drug reservoir, drug concentration & storage conditions methods should be documented Should be evidence based with reference ASHP Guidelines on Quality Assurance for Pharmacy Prepared Sterile Products ASHP: American Society Of Health-System Pharmacists
23 Documentation Training & competency evaluation of employees in sterile product procedures Refrigerator temperatures Certification of cabinets Dispensing records for cytotoxic products Documentation of dose calculations & batch preparation record Worksheet preparation ASHP Guidelines on Quality Assurance for Pharmacy Prepared Sterile Products ASHP: American Society Of Health-System Pharmacists
24 Labeling Patient name and identification Batch no if batch prepared All solution & ingredient names, amounts,strengths & concentrations Expiration date ( and time when applicable) Volume of regimen, flow rate and route Appropriate auxiliary labeling Storage requirements Identification of pharmacist/staff in charge Contact numbers ASHP Guidelines on Quality Assurance for Pharmacy Prepared Sterile Products ASHP: American Society Of Health-System Pharmacists CYTOTOXIC DRUG HANDLE WITH CARE
25 End Product Evaluation container leaks container integrity solution cloudiness particulates in the solution appropriate solution colour solution volume when preparation is completed verification that product was reconstituted accurately ASHP Guidelines on Quality Assurance for Pharmacy Prepared Sterile Products ASHP: American Society Of Health-System Pharmacists
26 Audit Verify the effectiveness of a quality management system Hands-on management tool for achieving continual improvement
27 Audit Tools Can be developed and tested in cancer centres (with cytotoxic drug preparation service) Can be used to assess current procedures complies to established standards Areas to look into: - microbiological testing of facility (air sampling every month) - checking procedures ( drug and dosage errors) - facility maintenance ( cabinets and cleanrooms every 6 months) - staff validation - safety measures among staff ( nurses, pharmacists)
28 ISOPP Audit Tool
29 Audit Report Negative Positive Improve Corrective Actions Highlight & Share
30 Audit on Work Process to Complete Prescription Orders In CDR Unit 1. Chemotherapy prescriptions from Daycare Oncology ward from Sept 2011 to Nov Parenteral chemotherapy prescriptions which require preparation in clean room 3. Prescriptions received during office hours on weekdays (Mon-Fri)
31 Receive indent from doctors in ward Printing of cytotoxic drug prescription Preparation of worksheet and labelling of cytotoxic drugs Verification & confirmation by pharmacist if the dose or regimen in prescription is ambiguous Filling of cytotoxic drugs into cytotoxic drug bags Preparation of cytotoxic drugs in clean room Dispensing of cytotoxic products on trolley Collection by staff nurse from wards Fig1: Summary of the processes involved from prescription indenting in the Pharmacy system to completion of chemotherapy prescription order
32 September November 2011 All Daycare Oncology cases were evaluated (N=218) Receive indent from doctors in ward Printing of cytotoxic drug prescriptions Preparation of worksheet and labeling of cytotoxic drugs Verification & confirmation by pharmacists if the dose or regimen in prescription is ambiguous Filling of cytotoxic drugs into cytotoxic drug bags Figure 4: Flow chart on the recruitment and exclusion of DayCare Oncology Cases 3 cases excluded Preparation of cytotoxic drugs in clean room 9 cases excluded Dispensing of cytotoxic products on trolley Collection by staff nurse from wards Only 206 cases were analyzed in the study 32
33 Duration (min) Tindent Tprint Twsheet Tverify Tfilling Tprepare Tdispense Figure 3: Comparison of mean of time taken for each process
34 Table 2: Time taken from one process to another process Indent Worksheet Filling Dispense Print Verify Prep Collect 1to 2 2to3 3to4 4to5 5to6 6to7 7to8 n Mean (min) 2.97 ± ± ± ± ± ± ± Median (min) Minimum (min) Maximum (min)
35 50 45 Figure 4: Comparison of median of time taken from one process to another process Duration (min) Trolley Collection >2 2-->3 3-->4 4-->5 5-->6 6-->7 7-->8
36 Findings of the Audit: 1. Time of preparation Only one technician reconstituting drugs. Drug reconstitution is a highly skilled procedure. Requires full concentration to prevent errors. 2. Time of filling NF drugs (purchase from kedai farmasi) 3. Time of worksheet >1 cytotoxic drugs per patient Change of dose by prescriber, time taken to redo worksheet 4. Trolley to Collection Delay of collection from ward staff Only one PK involved in collection 5. Worksheet to Verify Only one CDR pharmacist to verify all worksheets Error in labeling done by inexperienced personnel (student & PRP)
37 Conclusion - The pharmacy should have written policies and procedures which is - available to all personnel involved in cytotoxic drug preparation - important for personnel to understand before being allowed to prepare cytotoxic preparations - allows personnel competency to be assessed periodically - ISOPP Standard of Practice for Safe Handling of Cytotoxic Agents is a powerful instrument because of its global acceptance and distribution. - The audit tool completes the standards and helps the hospital to evaluate and progress.
38 References: ASHP: ASHP technical assistance bulletin on quality assurance for pharmacy - prepared sterile products:am J Hosp Pharm. 1993; 50: Brier K Leo. Evaluating aseptic technique of pharmacy personnel. Am J Hosp Pharm. 1983;40:400-3 Buchanan E. Clyde, et al. Principles of sterile product preparation. Bethesda, MD: American Society of Health-System Pharmacists, 1995 National Institute for Occupational Safety and Health, available at USP United States Pharmacopeia. Pharmaceutical compounding sterile preparations (general chapter 797) in: second supplement to UPS 31-NF 26: 2008
Pharmacy. Medication. Checks
Pharmacy Medication Checks Module 2 Table of Contents Section A... 1 A.1 Clinical Medication Order Check... 1 A.2 Final Product and Computer Order Entry Check... 1 Section B... 2 B.1 Documentation of Pharmacy
More informationCompounding Aseptic Isolators (CAI) James T Wagner
Compounding Aseptic Isolators (CAI) James T Wagner jimwagner@cenvironment.com Disclaimer "Although I am a member of the USP Sterile Compounding Expert Committee, I am speaking today in my individual capacity
More informationSterile Compounding elearning Course Curriculum 28 lessons with 33 hours of CE. Fundamentals of Sterile Compounding (8 lessons/8 hours CE)
Sterile Compounding elearning Course Curriculum 28 lessons with 33 hours of CE CriticalPoint s Sterile Compounding elearning curriculum is written by industry experts and covers both Chapter and
More informationChapter WAC Compounding Practices Crosswalk
Chapter 246-878 WAC Compounding Practices Crosswalk Draft WAC Language WAC 246-878-001 Purpose. 1) The requirements of this chapter apply to any person or facility that possesses a license under 18.64
More informationCompounding Questions and Answers
Compounding Questions and Answers JANUARY 10, 2011 1. Question: What is a reliable supplier? Answer: Some examples of reliable suppliers are FDA licensed manufacturers, CA Department of Public Health Food
More informationSterile Compounding elearning Course Curriculum 28 lessons with 33 hours of CE. Fundamentals of Sterile Compounding (8 lessons/8 hours CE)
Sterile Compounding elearning Course Curriculum 28 lessons with 33 hours of CE Fundamentals of Sterile Compounding (8 lessons/8 hours CE) The History of Compounding and USP Sterile Compounding Chapters
More informationUSP CHAPTER <797> INTRODUCTION RISK LEVELS
USP CHAPTER INTRODUCTION RISK LEVELS Introduction: The objective of this chapter is to describe conditions and practices to prevent harm, including death, to patients that could result from 1) microbial
More informationUNDER SECRETARY FOR HEALTH S INFORMATION LETTER MICROBIOLOGICAL ASSESSMENT OF PHARMACEUTICAL CLEANROOMS
DEPARTMENT OF VETERANS AFFAIRS Veterans Health Administration Washington DC 20420 IL 10-2006-008 In Reply Refer To: 10NB UNDER SECRETARY FOR HEALTH S INFORMATION LETTER MICROBIOLOGICAL ASSESSMENT OF PHARMACEUTICAL
More informationMeeting of the Minds: Pharmacy Services and Integration
Meeting of the Minds: Pharmacy Services and Integration RICK ABBOTT- B.Sc (Pharm) Regional Pharmacy Manager, Systemic Therapy, Eastern Health, Pharmacy Services CAROLE R. CHAMBERS- B.Sc (PHARM), MBA Pharmacy
More informationMINIMUM REQUIREMENTS FOR A VENDOR
MINIMUM REQUIREMENTS FOR A VENDOR When outsourcing the production of sterile products the first step in vendor evaluation is to see if they meet the minimum requirements. We ve developed a group of questions
More informationUSP Chapter 823 USP 32 (old) vs. USP 35 (new)
USP Chapter 823 USP 32 (old) vs. USP 35 (new) Sally W. Schwarz, MS, BCNP Research Associate Professor of Radiology Washington University School of Medicine St. Louis, MO Why USP Chapter ? FDA has
More informationOverview of a sterility assurance program for PET drugs
Coalition for PET Drug Approval Radiopharmaceutical Sciences Council Overview of a sterility assurance program for PET drugs Eric Webster, PETNET Solutions Disclosures Employee of PETNET Solutions, a Siemens
More informationPharmacy Compounding: Infection Prevention
Pharmacy Compounding: Infection Prevention Sam Eberwein, PharmD, MS, BCPS Clinical Manager, Sterile Products Area, Perioperative Services, & Special Formulations UNC Medical Center Department of Pharmacy
More informationStudy Summary. Results: All tested media-filled vials were negative for growth of any microorganisms.
A 7 Days Microbial Ingress Test of Single Use Vials Utilizing the EQUASHIELD Closed System Drug Transfer Device Study by Nelson Laboratories (Salt Lake City, UT) 2013, updated in 2014* Study Summary Abstract:
More informationUSP <800> A practical approach to compliance. Ryan W. Naseman, PharmD, MS, BCPS Michael Storey, PharmD, MS, BCPS
USP A practical approach to compliance Ryan W. Naseman, PharmD, MS, BCPS Michael Storey, PharmD, MS, BCPS Learning Objectives Explain the need for USP from an employee safety standpoint Describe
More informationSFHPHARM18 - SQA Unit Code FA2L 04 Prepare aseptic products
Overview This standard covers the preparation of aseptic products including preparing the environment and self. It covers aseptic preparation for both dispensing and manufacturing. Your practice will be
More informationAutomated compounding for intravenous chemotherapy
Automated compounding for intravenous chemotherapy Not valid for printing! Low resolution PDF file. For high resolution files, please contact Communication & Image Dept. The correct preparation and administration
More informationFDA s Guidance for Industry
Sterile Drug Products Produced by Aseptic Processing - CGMPs Midwest FDC Conference November 4 2005 Susan Bruederle, Investigator FDA / ORA / Central Region Chicago District / Hinsdale IL FDA s Guidance
More informationAnnex A2. Guidance on Process Validation Scheme for Aseptically Processed Products
Annex A2 Guidance on Process Validation Scheme for Aseptically Processed Products 1 Table of content 1 PURPOSE... 3 2 SCOPE... 3 3 GENERAL INFORMATION... 3 4 INFORMATION NEEDED FOR ASEPTIC PROCESSES VALIDATION...
More informationGuidelines for Design of. Compounded Sterile Products (CSPs) Facility
State of Kuwait Ministry of Health Infection Control Directorate Task Force Group for Designs and Constructions of Health Care Facilities Guidelines for Design of Compounded Sterile Products (CSPs) Facility
More informationUSP 797 & 800 Pharmacy Overview. (Presented to Vermont Chapter of New England Healthcare Engineers May 2016)
USP 797 & 800 Pharmacy Overview (Presented to Vermont Chapter of New England Healthcare Engineers May 2016) Overview Background and Regulatory Need United States Pharmacopeia (USP) 797 Purpose/Goals USP
More information2008 ASHP Summer Meeting Seattle, Washington Educational Session Abstracts
2008 ASHP Summer Meeting Seattle, Washington Educational Session Abstracts 116 USP Update 2008 and Personnel-Related Environmental Sampling Trissel, L.A. TriPharma Research, P.O. Box 265, Cashiers,
More informationHistory and Update of Chapters 797 and 800
United States Pharmacopeia (USP) History and Update of Chapters 797 and 800 Lisa D. Ashworth, BS Pharm, RPh, FACA 50 th Annual C.E. Seminar Saturday, January 27, 2018, Dallas, Texas Disclaimer The views
More informationWhere Quality Meets Flexibility
Where Quality Meets Flexibility is an industry leading 503B Outsourcing Facility providing sterile and non-sterile compounding services to hospitals, surgery centers, clinics, researchers & patients nationwide.
More informationThis compilation of the complex
Manufacturing in a Global Marketplace Reference Matrices on Regulations for Classified (Environmentally Controlled) Areas Betty Seawell, William Miele, and Jean Huxsoll The complex world of international
More informationSeptember 2, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
September 2, 2014 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: FDA Draft Guidance: Current Good Manufacturing Practice Interim
More informationUSP <797> Compliance Common Challenges and Potential Solutions
USP Compliance Common Challenges and Potential Solutions Angela Yaniv, Pharm.D Assistant Director - Sterile Products May 2, 2017 - OSHP Annual Meeting Angela Yaniv has no actual or potential conflict
More informationSummary of USP* 797 Pharmaceutical Compounding Sterile Preparations
Summary of USP* 797 Pharmaceutical Compounding Sterile Preparations Source of base information Pharmacopeial Form Vol 29 (4) July Aug. 2003 Effective date January 1, 2004 FDA enforceable Scope The content
More informationResponding to an FDA 483
Responding to an FDA 483 Jim Melancon VP, Associate General Counsel BioScrip, Inc. Marc Stranz, PharmD Healthcare Consultant Disclosure The speakers declare no conflicts of interest or financial interest
More informationBRIEFING 797 PHARMACEUTICAL COMPOUNDING STERILE PREPARATIONS INTRODUCTION
1 of 58 8/20/2010 9:20 PM BRIEFING 797 Pharmaceutical Compounding Sterile Preparations, USP 32 page 318. As a result of frequently asked questions from compounding practitioners and continuous reassessment
More informationCGMP Requirements for Investigational Products
PREP #6 CGMP Requirements for Investigational Products Ji-Eun Kim, RPh, PhD Research Pharmacist Regulatory Affairs Office of Research Compliance December 6, 2016 1 CME Disclosure Statement Northwell Health
More informationHospital Pharmacy Isolator Solutions for USP <797> Compliance from Esco
Hospital Pharmacy Isolator Solutions for USP Compliance from Esco Contents 1. Introduction 2. Clean Air Devices and Isolators 3. Cytotoxic Exposure 4. Esco Pharmacy Isolator (Positive Pressure Model)
More informationHAZARDOUS MATERIALS 7/7/2016 OR THE RIGHT-TO-KNOW HAZARD COMMUNICATION STANDARD (HCS) DISCLAIMER
HAZARD COMMUNICATION STANDARD (HCS) HAZARDOUS MATERIALS SAFE HANDLING Passed by Congress in 1988 with feedback from National Institute for Occupational Safety and Health (NIOSH) United States Pharmacopeia
More informationChemoLock. Setting a Whole New Standard for Hazardous Drug Safety. Don t you love it when everything just clicks? Introducing
Introducing ChemoLock Needlefree Closed System Transfer Device The first and only needlefree CSTD to receive FDA 510(k) clearance for both pharmacy (ONB) and patient administration (FPA) applications.
More informationPharmacy Quality Assurance Commission Sterile Compounding [USP <797>] Self-Assessment Compliance Checklist
STATE OF WASHINGTON Pharmacy Quality Assurance Commission Sterile Compounding [USP ] Self-Assessment Compliance Checklist Introduction: This checklist includes the reported principal competencies,
More informationMicrobiological Consideration for Non-Sterile Pharmaceutical
May 1-3, 2012 Javits Center New York, NY Microbiological Consideration for Non-Sterile Pharmaceutical Dr. Leonard W. Mestrandrea Principal Consultant MESTRANDREA CONSULTING LLC Title Date Microbial Control
More informationTwo part study simulated preparation and administration manipulations to determine containment of liquids, aerosols and vapors.
Table 1: Studies evaluating fluid leakage during preparation and administration First author and date of publication Comparator Method Detection Method Result Conclusions/ Implications Contamination comparison
More informationLearning Objectives. What is a Compounding Pharmacist? Disclosure
PHARMACY COMPOUNDING: Update on Trends & Regulations Michael Roberge, RPh Certified Compounding Pharmacist Owner, Compounded Solutions in Pharmacy LLC Monroe, CT Learning Objectives Define pharmacy compounding
More informationLUNCH AND LEARN. October 14, CE Activity Information & Accreditation
LUNCH AND LEARN USP Chapter : What s on the Radar? October 14, 2016 Featured Speaker: Patricia C. Kienle, RPh, MPA, FASHP Director, Accreditation and Medication Safety Cardinal Health Innovative Delivery
More informationInspection Form. DPP Information. Inspection Information. Staff Information. Service Information. DPP Designated Member. Street City Postal Code
Inspection Form DPP Information Name of DPP Owner Name of DPP (if different from owner's name) DPP Designated Member Designated Member Email Designated Member Phone number Street City Postal Code Phone
More informationChemoLock Needlefree Closed System Transfer Device
ChemoLock Needlefree Closed System Transfer Device Clinical Evidence Table of Contents Pg Number Studies Evaluating Environmental Contamination ph Liquid Integrity Test of FDA-Approved ONB Closed-System
More informationPERFORMANCE QUALIFICATION PROTOCOL HVAC SYSTEM
Page 1 of 24 PERFORMANCE QUALIFICATION PROTOCOL FOR HVAC SYSTEM Signing of this Performance Qualification Protocol indicates agreement with the Validation Master Plan approach of the equipment. Further
More informationUSP <797> and Environmental Sampling
USP and Environmental Sampling Participants will be in listen only mode. 9 a.m. (PT) Download the PDF: https://www.emlab.com/m/media/usp797-webinar.pdf Presented by: Michael Berg, Ph.D. Continuing
More informationOrange and Yellow Guides
PHARMACY PREPARATION ACROSS EUROPE IS THERE A LEVEL PLAYING FIELD? Dr. Alison M.Beaney Regional Quality Assurance Specialist North-East England PHARMACY PREPARATION ACROSS EUROPE IS THERE A LEVEL PLAYING
More informationPIC/S GUIDE TO GOOD PRACTICES FOR THE PREPARATION OF MEDICINAL PRODUCTS IN HEALTHCARE ESTABLISHMENTS
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PE 010-3 1 October 2008 PIC/S GUIDE TO GOOD PRACTICES FOR THE PREPARATION OF MEDICINAL PRODUCTS IN HEALTHCARE ESTABLISHMENTS
More informationFLORIDA SOCIETY OF HEALTH SYSTEM PHARMACISTS NOVEMBER 4, 2016 JAMES T WAGNER CONTROLLED ENVIRONMENT CONSULTING
Engineering Controls for Compliance with USP Chapters and FLORIDA SOCIETY OF HEALTH SYSTEM PHARMACISTS NOVEMBER 4, 2016 JAMES T WAGNER CONTROLLED ENVIRONMENT CONSULTING Learning and Performance
More informationTel: TTY: NOTICE OF PUBLIC HEARING
CHARLES D. BAKER Governor KARYN E. POLITO Lieutenant Governor The Commonwealth of Massachusetts Executive Office of Health and Human Services Department of Public Health Bureau of Health Professions Licensure
More informationDraft Guidelines for Radiopharmacy
Draft Guidelines for Radiopharmacy In the nuclear medicine laboratories (radiopharmacies) of nuclear medicine clinics in European hospitals, quality assurance varies from non-existent to good manufacturing
More informationfor IND and RDRC Regulated PET Compounding
Overview of USP Chapter for IND and RDRC Regulated PET Compounding Distributed Manufacturing of PET Radiopharmaceuticals for Multi-Center Clinical Trials SNM, Annual Meeting Toronto, Ontario, Canada
More informationUS Regulatory Requirements: Clinical & Clinical Research Production, SPECT & PET Radiopharmaceuticals (RPs)
US Regulatory Requirements: Clinical & Clinical Research Production, SPECT & PET Radiopharmaceuticals (RPs) 20 th International Symposium Radiopharmaceutical Sciences Jeju, Korea Pre-Symposium Workshop
More informationOPERATION INTRODUCTION
USP 39 Physical Tests / á795ñ Pharmaceutical Compounding Nonsterile 617 then either 1) select two nearby ph buffers from Table 2 or 2) select one from Table 2 and another documented prepared buffer that
More informationHeating, ventilation, and air system encompasses heating, ventilation, and air conditioning, which is integral component of
REVIEW ARTICLE Demand of pharmaceutical facility functionality: Validation and qualification of HVAC system Anamika Singh, Sapna Malviya, Anil Kharia Department of Quality Assurance of Modern Institute
More informationSupply of aseptically - prepared doses of IMPs across legal boundaries. Edition 1. December 2017
Supply of aseptically - prepared doses of IMPs across legal boundaries Edition 1 December 2017 Endorsed and supported by: NHS Pharmaceutical Quality Assurance Committee 2017 with National Pharmacy Clinical
More informationPHCT 401 Aseptic Processes & Techniques
PHCT 401 Aseptic Processes & Techniques Principles of Aseptic Techniques Aseptic Processing Sterility Testing Laminar flow air cleaning Quality Control Tests Personnel Principles of Aseptic Techniques
More informationControlled environments
AS 2252.5:2017 AS 2252.5:2017 Controlled environments Part 5: Cytotoxic drug safety cabinets (CDSC) Design, construction, installation, testing and use This Australian Standard was prepared by Committee
More informationOn behalf of the PHSS Pharmaceutical and Healthcare Sciences Society (UK).
31 st March 2015 Submission of comments on ' Concept paper on the revision of annex 1 of the guidelines on good manufacturing practice manufacture of sterile medicinal products EMA/INS/GMP/735037/2014
More informationPhEn-602 Notes # 4 J. Manfredi
PhEn-602 Notes # 4 J. Manfredi Spring 2009 1 Basic definitions Clean Room: A room in which the concentration of airborne particles is controlled and contains one or more clean zones Clean Zone: A defined
More informationCompleting. By the end of this chapter, you will be able to: Introduction. Chapter 16
Chapter 16 Completing Product Processing By the end of this chapter, you will be able to: l Explain the term cold chain l Describe the type of fridge used for correct storage of refrigerated products l
More informationGood Manufacturing Practices Purpose and Principles of GMP. Tony Gould
Good Manufacturing Practices Purpose and Principles of GMP Tony Gould Why GMP? Provides a high level assurance that medicines are manufactured in a way that ensures their safety, efficacy and quality Medicines
More informationWhy change is inevitable in aseptic manufacturing?
Why change is inevitable in aseptic manufacturing? Chrissie Fuchs, Marketing & Communication at Fedegari Group Sergio Mauri, Manager, Integrated Projects at Fedegari Group Key words: Aseptic manufacturing
More informationGuidelines for the Use of Cytotoxic or Chemotherapeutic Drugs
Guidelines for the Use of Cytotoxic or Chemotherapeutic Drugs Caltech Environment, Health and Safety 1200 E. California Blvd. M/C 25-6 Pasadena, CA 91125 626.395.6727 safety@caltech.edu www.safety.caltech.edu
More informationReview Validation of aseptic processes for pharmaceuticals
OPEM www.opem.org Oriental Pharmacy and Experimental Medicine 2010 10(4), 231-238 DOI 10.3742/OPEM.2010.10.4.231 Review Validation of aseptic processes for pharmaceuticals Lincy Joseph*, Mathew George
More informationNonsterile Compounding: USP and Best Practices for Community Pharmacists
Nonsterile Compounding: USP and Best Practices for Community Pharmacists Target Audience: Pharmacists and Pharmacy Technicians ACPE#: 0202-0000-18-033-L07-P/T Activity Type: Knowledge-based Disclosures
More informationASEPTIC DISPENSING FOR NHS PATIENTS. Contents. Page Numbers. 1. Introduction. 2. Scope. 3. Policies. 5. Process Validation. 6. Aseptic Processing
ASEPTIC DISPENSING FOR NHS PATIENTS ACKNOWLEDGMENTS The Department of Health would like to thank all those who contributed to this guidance document and, in particular, Dr. John Farwell who was the primary
More informationThanks and acknowledgement to Pamela Isaacs for the content and slides in this presentation.
A PRESCRIPTION FOR INFECTION PREVENTION ROUNDING IN THE PHARMACY EVELYN COOK Thanks and acknowledgement to Pamela Isaacs for the content and slides in this presentation. OBJECTIVES: 1. Discuss recent outbreaks
More informationá797ñ PHARMACEUTICAL COMPOUNDING STERILE PREPARATIONS
626 á795ñ Pharmaceutical Compounding Nonsterile / Physical Tests USP 39 Vehicle: A component for internal or external use that is used as a carrier or diluent in which liquids, semisolids, or solids are
More informationQuality is Our Promise.
Quality is Our Promise. Our goal at KRS Global Biotechnology is to provide the highest quality pharmaceutical preparations. We accomplish this with an unrivaled quality assurance and quality control program
More informationEAHP STATEMENT ON THE NEED FOR BARCODING OF THE SINGLE DOSE ADMINISTERED IN HOSPITALS
EAHP STATEMENT ON THE NEED FOR BARCODING OF THE SINGLE DOSE ADMINISTERED IN HOSPITALS JUNE 2012 (UPDATED FROM 2007 & 2010 STATEMENTS) What is meant by barcoding of the single dose? By single dose EAHP
More informationResolution CM/Res(2016)2 on good reconstitution practices in health care establishments for medicinal products for parenteral use
Resolution CM/Res(2016)2 on good reconstitution practices in health care establishments for medicinal products for parenteral use (Adopted by the Committee of Ministers on 1 June 2016 at the 1258th meeting
More informationWhitepaper. High temperature HEPA filtration. Dr.-Ing. Marc Schmidt, Dr.-Ing. Lothar Gail, Hugo Hemel MSc. Preview
High temperature HEPA filtration Air filtration challenges and answers for dry heat sterilization tunnels Whitepaper Preview Dr.-Ing. Marc Schmidt, Dr.-Ing. Lothar Gail, Hugo Hemel MSc. Air filtration
More informationINVESTIGATIONAL DRUG MANAGEMENT OVERVIEW
NORTHWELL HEALTH OFFICE OF RESEARCH COMPLIANCE STUDY FEASIBILITY AND APPROVAL Where can I learn about the investigational drug? Protocol Investigator s brochure Product insert or prescribing information
More informationAseptic Processing Current Issues & Trends
Aseptic Processing Current Issues & Trends 1 Introduction Richard M. Johnson Member, PDA for 20+ years President & CEO since 2009 Ladies and Gentlemen, I am happy to be here with you. Senhoras e Senhores,
More informationBioburden Contamination Control: A Holistic Overview
Bioburden Contamination Control: A Holistic Overview Scott Sutton, PhD Microbiology Network, Inc. Scott Sutton, PhD is the Principal of Microbiology Network, Inc (http:// microbiologynetwork.com/) a company
More informationCreating a Centralized Compounding Pharmacy within a Health System
SALAS BLANCAS Amy Benner, PharmD Director of Central and Shared Services Scripps Health. Robert Miller, MS Quality Manager Scripps Health Ensuring the production of accurate and safe sterile compounded
More informationThe interface between Good Clinical Practice and Good Manufacturing Practice
1 The interface between Good Clinical Practice and Good Manufacturing Practice your partner in compliance 1 The interface between GCP and GMP Generally, studies are designed and planned by physicians who
More informationSafe handling of cytotoxic drugs and cytotoxic waste ETLog GmbH Brunnenstraße Berlin Germany
Cytotoxic Waste Management Safe handling of cytotoxic drugs and cytotoxic waste ETLog GmbH Brunnenstraße 164 10119 Berlin Germany www.etlog.com info@etlog.com Safe Handling of Cytotoxic materials General
More informationBarcodes on Unit of Use
Barcodes on Unit of Use 1 What hospitals need Hospitals need medications Ready-to-Administer In Unit-of-Use With Barcode 2 What hospitals need Ready-to-Administer If not, must go through additional pharmacy
More informationPhaSeal Evidence. A summary of the published evidence of the effectiveness of the PhaSeal closed-system drug transfer device
PhaSeal Evidence A summary of the published evidence of the effectiveness of the PhaSeal closed-system drug transfer device TabLE of Contents Introduction The PhaSeal Closed-System Drug Transfer Device
More informationBRIEFING 1168 Compounding for Phase I Investigational Studies,
BRIEFING 1168 Compounding for Phase I Investigational Studies, PF 39(5) [Sept. Oct. 2013]. The current proposed chapter in PF 43(3) [May June 2017] is posted online at www.usp.org/usp-nf/notices/compounding-forphase-i-investigational-studies
More informationCurrent Trends in Sterile Manufacturing. by Sterling Kline, RA Director of Project Development Integrated Project Services (IPS)
Current Trends in Sterile Manufacturing by Sterling Kline, RA Director of Project Development Integrated Project Services (IPS) Executive Summary Drug developers go to great lengths to assure that their
More informationUSP<797> AND THE ASEPTIC PROCESSING OF RADIOPHARMACEUTICALS PART 1
USP AND THE ASEPTIC PROCESSING OF RADIOPHARMACEUTICALS PART 1 INTRODUCTION The learner was introduced to the guidelines of USP Chapter in a previous Continuing Education lesson, USP Compliance
More informationEnvironmental Monitoring of Aseptic Processing Areas - 1
Environmental Monitoring of Aseptic Processing Areas - 1 A war against an invisible enemy DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 1 Training Course Agenda Overview of Environmental Monitoring
More informationTITLE: Research Pharmacy Standard Policy SOP #: INV-100 Page: 1 of 5 Effective Date: 8/31/17
SOP #: INV-100 Page: 1 of 5 1. POLICY STATEMENT: DF/HCC research pharmacies follow a standard set of policy requirements for clinical trials. 2. BACKGROUND: None 3. RESPONSIBLE PERSONNEL: 3.1. Research
More informationSolutions for All Your Aseptic Parenteral Drug Formulation/Filling Needs. BUBBLE-FREE FILLING : A New Option in Prefilled Syringe Filling
WHITEPAPER Hyaluron Contract Manufacturing Solutions for All Your Aseptic Parenteral Drug Formulation/Filling Needs BUBBLE-FREE FILLING : A New Option in Prefilled Syringe Filling Introduction The advent
More informationProfiles in CSP Insourcing: Scripps Health
Profiles in CSP Insourcing: Scripps Health Robert Eastin, Pharm.D. Director, Central Pharmacy and Shared Services Scripps Health Hospital Profile Scripps Health is a private, nonprofit integrated health
More informationWhitepaper Cross-Contamination
Whitepaper Cross-Contamination Protection in HVAC I N D U S T R Y I N S I G H T S Norman A. Goldschmidt September 30, 2011 Principal, Engineering www.geieng.com I N D U S T R Y I N S I G H T S Genesis
More informationAseptic Process Validation
Aseptic Process Validation IMB GMP Information Seminar 27 th September 2012 Gerard Sheridan, Inspector Date Insert on Master Slide Slide 1 Overview Guidance Best Practices Common Deficiencies Slide 2 Aseptic
More informationCANADA (HEALTH CANADA)
1 GMP GAZETTE TM May 2016 HPFBI CANADA (HEALTH CANADA) No updates NNHPD NHPs Final Monograph for Antiseptic Skin Cleanser Who`s Affected? Companies seeking NPN or DIN for topical antiseptic hand cleansers
More informationThe GAP Analysis for Nonsterile Compounding
VOLUME 17 NUMBER 2 Current & Practical Compounding Information for the Pharmacist provided for by a grant from Perrigo Pharmaceuticals Goal: To provide background information and practical procedures for
More informationEUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS
EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guidance on CPD for QUALIFIED PERSONS EIPG Guidance on CPD for QP Continuing Professional Development for Qualified Persons, Technical Directors and other Responsible
More informationHEALTHCARE. BoxPicker Automated Pharmacy Storage System
HEALTHCARE BoxPicker Automated Pharmacy Storage System BoxPicker Automated Pharmacy Storage System BoxPicker is part of an end-to-end integrated solution of Swisslog equipment and software that controls
More informationPorton Biopharma Limited 1/17/17
Porton Biopharma Limited 1/17/17 10903 New Hampshire Avenue Silver Spring, MD 20993 Via UPS Warning Letter 320 17 19 Return Receipt Requested January 19, 2017 Dr. Roger J. Hinton Managing Director Porton
More informationSecundum Artem. USP Chapter <795> Pharmaceutical Compounding - Nonsterile Preparations INTRODUCTION BACKGROUND VOLUME 13 NUMBER 4
VOLUME 13 NUMBER 4 Secundum Artem Current & Practical Compounding Information for the Pharmacist. USP Chapter Pharmaceutical Compounding - Nonsterile Preparations GOALS AND OBJECTIVES Goal: The goal
More informationGeneral European OMCL Network (GEON) QUALITY MANAGEMENT DOCUMENT
General European OMCL Network (GEON) QUALITY MANAGEMENT DOCUMENT PA/PH/OMCL (16) 86 R2 MANAGEMENT OF ENVIRONMENTAL CONDITIONS Full document title and reference Document type Management of Environmental
More informationPreparing Your Aseptic Processing Facility for an FDA Inspection. Valerie Welter, Director Quality Bayer HealthCare March 10, 2014
Preparing Your Aseptic Processing Facility for an FDA Inspection Valerie Welter, Director Quality Bayer HealthCare March 10, 2014 Agenda Regulatory Requirements Establishing your Approach Aseptic Controls
More informationCancer Vanguard. Biosimilars Trust Policy Template
Cancer Vanguard Biosimilars Trust Policy Template Aim of this document: The document provides generic guidance and outline for the development of local trust policies in relation to the adoption of biosimilars
More informationEnsuring Quality Pharmacy Compounding: Implications for Pharmaceutics Education
Ensuring Quality Pharmacy Compounding: Implications for Pharmaceutics Education Loyd V. Allen, Jr., Ph.D. Professor & Chair Emeritus University of Oklahoma HSC College of Pharmacy Editor-in in-chief International
More informationSterility Assurance Level and Aseptic Manufacturing Process in Pharmaceuticals
Review Article ISSN 2277-3657 Available online at www.ijpras.com Volume 3, Issue 4 (2014),10-15 International Journal of Pharmaceutical Research & Allied Sciences Sterility Assurance Level and Aseptic
More information